Relation between serum sodium levels and prognosis in outpatients with chronic heart failure: Neutral effect of treatment with beta-blockers and angiotensin-converting enzyme inhibitors: Data from the Italian network on congestive heart failure (IN-CHF database)

Journal of Cardiovascular Medicine

Volumn 12, Issue 10, 2011, Pages 723-731

  Baldasseroni, Samuele ^a   Urso, Renato ^b   Orso, Francesco ^a   Bianchini, Bianca P ^c   Carbonieri, Emanuele ^d   Cirò, Antonio ^d   Gonzini, Lucio ^b   Leonardi, Giuseppe ^d   Marchionni, Niccolò ^a   Maggioni, Aldo P ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b ANMCO RESEARCH CENTER   (Italy)

^c Orlandi Hospital   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

Author keywords

angiotensin converting enzyme inhibitors; beta blockers; heart failure; hyponatremia; prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SODIUM;

ADULT; ARTICLE; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM BLOOD LEVEL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; HYPONATREMIA; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; OUTPATIENTS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SODIUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052620716     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32834ae87e     Document Type: Article

References (26)

1. Kumar S, Berl T. Sodium. Lancet 1998; 352:220-228. (Pubitemid 28329332)
2. Adroguè HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342:1581-1589. (Pubitemid 30340505)
3. Oren RM. Hyponatremia in congestive heart failure. Am J Cardiol 2005; 95:2B-7B. (Pubitemid 40545926)
4. Lilly LS, Dzau VJ, Williams GH, et al. Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J Clin Endocrinol Metab 1984; 59:924-930. (Pubitemid 14020694)
5. LeJemetel TH, Serrano C. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure. Int J Cardiol 2007; 120:1-7.
6. Spital A. Diuretic-induced hyponatremia. Am J Nephrol 1999; 19:447-452. (Pubitemid 29397071)
7. Clark BA, Shannon RP, Rosa RM, Epstein FH. Increased susceptibility to thiazide-induced hyponatremia in the elderly. J Am Soc Nephrol 1994; 5:1106-1111. (Pubitemid 24977088)
8. Fried LF, Palewsky PM. Hyponatremia and hypernatremia. Med Clin North Am 1997; 81:585-609. (Pubitemid 27220641)
9. Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure. Circulation 2005; 111:2454-2460.
10. Gheorghiade M, Abaham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF Registry. Eur Heart J 2007; 28:980-988. (Pubitemid 47343897)
11. Kearney MT, Fox KAA, Lee AJ, et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol 2002; 40:1801-1808. (Pubitemid 35341959)
12. Lee Wh, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 2:257-267. (Pubitemid 16127402)
13. Baldasseroni S, Opasich C, Gorini M, et al., on behalf of the Italian Network on Congestive Heart Failure Investigators. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in5517. outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002; 143:398-405. (Pubitemid 34185169)
14. Swedberg K, Cleland J, Dargie H, et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115-1140.
15. Lang RM, Bierig M, Devereux RB, et al., Chamber Quantification Writing Group. American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463. (Pubitemid 41821197)
16. Dazau VJ, Parcker M, Lilly LS, et al. Prostaglandins in severe congestive heart failure: relation to activation of renin-angiotensin system and hyponatremia. N Engl J Med 1984; 310:347-352. (Pubitemid 14179539)
17. Lilly SL, Dazau VJ, William GH, et al. Hyponatremia in congestive heart failure: implications for neurohormonal activation and responses to orthostasis. J Clin Endocrinol Metabol 1984; 59:924-930.
18. Dargie HJ, Cleland JG, Leckie BJ, et al. Relation of arrhythmias and electrolyte abnormalities to survival in patients with severe chronic heart failure. Circulation 1987; 75 (Suppl IV):98-107.
19. Saxon LA, Stevenson WG, Middlekauff HR, et al. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1993; 72:62-65. (Pubitemid 23184364)
20. Kumar S, Rubin S, Mather PJ, Whellan DJ. Hyponatremia and vasopressin antagonism in congestive heart failure. Clin Cardiol 2007; 30:546-551. (Pubitemid 350209965)
21. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290:2581-2587. (Pubitemid 37443288)
22. Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 2007; 167:1998-2005. (Pubitemid 47606641)
23. Vazquez R, Bayes-Genis A, Cygankiewicz I, et al., on behalf of the MUSIC Investigators. The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J 2009; 30:1088-1096.
24. Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003; 146:9-18. (Pubitemid 36851295)
25. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) investigators: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297:1319-1331. (Pubitemid 46513233)
26. Paterna S, Parrinello G, Fasullo S, et al. Normal sodium diet versus low sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin Sci 2008; 114:221-230. (Pubitemid 351293997)